Skip to main
HUMA

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte is positioned for long-term success due to its regained ex-U.S. rights for Symvess, giving the company more flexibility to tailor partnerships and potential for non-dilutive capital. The company's advancing global expansion, with the MAA acceptance for Symvess in Israel and ongoing efforts in other international markets, also supports its potential growth. However, risk factors such as clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks should still be monitored as the company progresses.

Bears say

Humacyte is currently developing and commercializing acellular tissue engineered vessels for various indications, including vascular trauma and hemodialysis access. While the company has made progress in terms of regulatory approvals and international partnerships, their product sales have been relatively low and they have yet to achieve profitability. Additionally, their planned expansion into other indications and geographic markets may face challenges and competition from other vascular repair technologies.

Humacyte (HUMA) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Buy based on their latest research and market trends.

According to 7 analysts, Humacyte (HUMA) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.